Preclinical Study of Therapeutic Efficacy of a New Russian Radiopharmaceutical <superscript>177</superscript>Lu-DOTA-PSMA.
In: Bulletin of Experimental Biology & Medicine, Jg. 176 (2023-12-01), Heft 2, S. 224-226
Online
academicJournal
Zugriff:
The therapeutic efficacy of a Russian radiopharmaceutical 177Lu-DOTA-PSMA was studied in vivo using male BALB/c nu/nu (nude) mice with prostate carcinoma 22Rv1 xenografts by tumor growth inhibition criterion. The mean tumor volumes in mice treated with 177Lu-DOTA-PSMA were significantly lower than in animals of the control group. There were no significant differences in the values of tumor growth inhibition between the groups of animals receiving 3.7 or 7.4 MBq of 177Lu-DOTA-PSMA. [ABSTRACT FROM AUTHOR]
Titel: |
Preclinical Study of Therapeutic Efficacy of a New Russian Radiopharmaceutical <superscript>177</superscript>Lu-DOTA-PSMA.
|
---|---|
Autor/in / Beteiligte Person: | Tishchenko, V. K. ; Vlasova, O. P. ; Lebedeva, A. A. ; Fedorova, A. V. ; Pankratov, A. A. ; Morozova, N. B. ; Kuzenkova, K. A. ; Stepchenkova, E. D. ; Shegai, P. V. ; Ivanov, S. A. ; Kaprin, A. D. |
Link: | |
Zeitschrift: | Bulletin of Experimental Biology & Medicine, Jg. 176 (2023-12-01), Heft 2, S. 224-226 |
Veröffentlichung: | 2023 |
Medientyp: | academicJournal |
ISSN: | 0007-4888 (print) |
DOI: | 10.1007/s10517-024-05999-z |
Schlagwort: |
|
Sonstiges: |
|